Expanded Access Program of Dupilumab in Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy Who Have Been Previously Treated With Linvoseltamab and Background Dupilumab in the Parent Study R5458-668-ALG-2219 (NCT06369467)

N/ANo Longer AvailableNCT06631677

Regeneron Pharmaceuticals

Overview

This is an expanded access program of dupilumab that was never initiated and, therefore, not available.

Study Type

EXPANDED_ACCESS

Administered per protocol

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.